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was 29.2%. In patients with endoscopic remission at Week 10, the IBDQ remission
rate was 69.7% compared with 33.3% in patients not reaching endoscopic remis-
sion. Similar results were observed at Week 54. CONCLUSIONS: Treatment with
CZP at the recommended dose resulted in substantial improvement in HRQoL at 10
and 54 weeks of therapy, measured by the IBDQ. Higher rates of IBDQ remission
were associated with endoscopic remission compared with nonremission, war-
ranting further evaluation of CZP therapy on HRQoL in CD. †Dr Lémann died on
August 26, 2010. We mourn the loss of our esteemed colleague.
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KENYA’S VILLAGE AGING INSENSITIVITY TO AGING POLICIES
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OBJECTIVES: Since independence in Kenya in 1963, there has been great challenges
on policy making with regards to the village elderly and ageing. Inspite of our
current advocacies, sensitization and awareness programmes being carried out by
local non governmental humanitarian bodies and faith based entities, Kenyan el-
derly and ageing men and women lack government concern, services and new
policies on especially the ageing village vulnerable ill-health policy and services in
their life insurance The aim and purpose of my paper is to highlight worthy ap-
proaches and to identify areas of need as a priority in overcoming the impasse in
Kenyan policy on ageing and health. METHODS: We conducted a village research
on a door to door basis on policy and health development through Questionare as
part of a research project on dimensions and actions of health in old age in rural
communities in western Kenya and its policy implications. RESULTS: Five very
sensitive areas of evidence of lack of awareness and government lack of action to
the aged and ageing groups were highlighted. And required to (1) sensitize and give
strength to the case on why action on old age-related health should be pursued,
and (2) what action be taken to bring to light the uncertainties of the aged and
ageing groups in Kenyas most forgotten rural insensitive communities.
CONCLUSIONS: A continued formal research system on the five areas is essential
to promote awareness of policies on aged and ageing groups in the insensitive
villages and advocacy towards their ignorance and plight on matters related to
their life insurance, policy making and advancement towards scientific debate on
ageing and their health in the global community.
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OBJECTIVES: Cost of prescriptions is a large portion of the nation’s health care
expenditure. In 2007, the Kaiser Family Foundation estimated total prescription
costs to be $202 billion, demonstrating a large burden to the US economy. This
study evaluates determinates of non-opioid analgesic (NOA) prescribing patterns
in the USA from the National Ambulatory Medical Care Survey (NAMCS) from
2002-2007. METHODS: NOA prescribing trends were determined using drug codes
from NAMCS data. The data was collected on patients greater than 18 years, with
ICD-9-CM codes for chronic-non-cancer pain as reasons for office visits. The study
used cross-sectional analysis. A logistic model reported determinants of NOA in
the study population. RESULTS: A total of 22,967 analgesic prescriptions were pre-
scribed from 2002-2007 for men (37%) and women (63%) 18 years or older. Men were
1.46 times more likely (p0.05) to receive NOA than Women. Medicare and Medic-
aid patients were 42% (p0.01) and 44% (p0.01) more likely to receive NOA than
patients with other insurance types. Patients seen by primary care physicians
(PCPs) were 56% (p0.05) more likely to receive NOA than by non-PCPs. Low back
pain (LBP) patients were 60% more likely to get NOA prescribed than patients with
non-LBP. Geographical location was a statistically insignificant factor relating to
the likelihood of a being prescribed NOAs. Socio-economic, education, lifestyle,
diet, age group, ethnicity, and mental health status were also found to be
insignificant. CONCLUSIONS: Men, patients with Medicare, Medicaid, and LBP
were more likely to receive prescriptions for NOA. Physicians managing patients at
risk of receiving NOA, reported in our results, may benefit from seeking evidence
based policy for maximizing pain control in a cost-effective way.
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OBJECTIVES: Provide an overview of the burden of BC and of BC care and outcomes
in LAC.METHODS: Review of literature (PubMed, LILACS, SCIELO), public databases
(Globocan 2002 & 2008, CEPALSTAT, DIRAC, PAHO, WHOSYS, etc) and conference
presentations (ASCO, ISPOR). Latin-American experts and patient organizations
were surveyed. RESULTS: A total of 114,900 women present with and 37,000 die of
BC annually in LAC. BC exhibits the highest incidence and mortality of all cancers,
is steadily increasing and is expected to double by 2030. Age is the principal risk
factor. High incidence in Argentina and Uruguay (ASR 74-91/100,000) and younger
age at diagnosis and death (mean 57y) in Peru, Mexico, Colombia and Brazil trans-
late into a heavy burden. LAC’s low 5-year survival (70-75%) is partly because
30-40% patients are diagnosed in metastatic phases III and IV. However, BC mor-
tality-to-incidence ratios (MIR) improvements are noticeable when comparing
MIR2002 vs. MIR2008. Best MIRs are registered in Argentina, Uruguay and Chile.
Costa Rica shows the most progress; Brazil, Mexico and Panama have not improved
significantly. Suboptimal prevention policies; vast inequalities in access to diagno-
sis and treatment, a fragmented organisation and management of BC care, and
poor uptake of evidence-based best practices were observed. Universal healthcare
coverage is not the rule in LAC and, even in those countries where access to BC
health services is guaranteed by law; resources are insufficient. Availability of BC-
specialized surgeons, waiting times, node clearance policy and access to breast
reconstruction vary greatly across countries and between public and private set-
tings. Radiotherapy equipment is insufficient (except Uruguay, Chile, Venezuela).
All modern systemic therapies are available but some not widely diffused for cost
considerations. Palliative care is developing but, despite great efforts, many prob-
lems persist. CONCLUSIONS: Women go undiagnosed, uncared for or treated with
suboptimal therapies; which results in high morbidity and associated societal
costs.
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OBJECTIVES: At the end of 2006, there was an important reform in the Hungarian
pharmaceutical market, including serious changes in the health insurance reim-
bursement of medicines. The aim of our study is to analyze the changes in the
Hungarian health insurance pharmaceutical budget between 2006-2009.
METHODS: Data were derived from the nationwide administrative dataset of the
National Health Insurance Fund Administration (OEP), the only health care financ-
ing agency in Hungary. We analyzed the changes of the pharmaceutical budget
between 2006-2009. Results are given in Hungarian Forint (HUF), US dollars (USD)
and Euro (EUR). The annual average currency exchange rates were applied accord-
ing to the data of the Central Bank of Hungary. RESULTS: In the first year, the
Hungarian pharmaceutical budget decreased from 388.7 billion HUF (2006) to 323.6
billion HUF (2007) by 65.1 billion HUF (16.7 %). This decrease was a bit moderate
both in Euro (0.18 billion EUR, 12.4 %) and in USD dollar (0.1 billion USD, 4.7 %) due
to the stronger Hungarian currency. For 2009, the pharmaceutical budget slightly
increased compared to 2007 up to 343.2 billion HUF which resulted in a decrease
from 2006 to 2009 by 45.5 billion HUF (11.7 %). The decrease between 2006-2009 was
more significant both in Euro (0.25 billion EUR, 16.8 %) and in USD dollar (0.15 billion
USD, 8.1 %) due to the weakened Hungarian currency. CONCLUSIONS: Due to the
reform of the whole Hungarian pharmaceutical market, the Hungarian health in-
surance pharmaceutical budget significantly decreased between 2006-2009. This
decrease was moderate in EUR or USD between 2006-2007, however between 2006-
2009 it became higher as the Hungarian currency weakened compared to EUR or
USD during the world economic crisis.
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OBJECTIVOS: Realizar un análisis teórico de las preferencias del paciente derivado
de la elección entre dos bienes: un medicamento biotecnológico de patente y un
medicamento biosimilar. METODOLOGÍAS: Suponemos que son bienes sustitutos
perfectos, pues el paciente no puede consumir los dos bienes al mismo tiempo,
debe elegir entre uno u otro. Definimos la función de utilidad del paciente como
U(BT,BS)aBTbBS. Donde, BT es el Biotecnológico de patente, BS Biosimilar, a es la
seguridad y eficacia del medicamento BT y b seguridad y eficacia del medicamento
BS. Entre más seguro y eficaz sea el medicamento el paciente lo prefiere más. Entre
mayor sea U su estado de salud es mejor. Suponemos que BT tiene estudios clínicos
confiables que demuestran su seguridad y eficacia y que BS no presenta estudios
clínicos y no se sabe su seguridad y eficacia real, por lo tanto BT es preferido, es
decir ab. El paciente posee una restricción presupuestal determinada por la ec-
uación yPBTBTPBSBS. Derivado de las inversiones en estudios clínicos supo-
nemos que PBTPBS. La tasa marginal de sustitución está determinada por la pen-
diente -a/b, es decir que el paciente sacrificará una unidad de BT por b/a unidades
del bien BS. Dada la restricción presupuestal, la pendiente y tasa de sustitución
objetivo es -PBT/PBS. RESULTADOS: De acuerdo a las preferencias del consumidor,
su consumo óptimo se determinan de acuerdo a lo siguiente, si PBT/PBSa/b solo
consumirá BT, si PBT/PBSa/b entonces el paciente solo consumirá BS, y si PBT/
PBSa/b el paciente está indiferente entre consumir BT o BS. CONCLUSIONES:
Podemos concluir que las preferencias del paciente son sensibles al precio y a la
seguridad y eficacia del medicamento. Entre más seguro y eficaz sea BT el paciente
lo prefiere y estará dispuesto a pagar más.
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